Analysis of ALKA-372-001, STARTRK-1, and STARTRK-2 trials demonstrated prolonged survival with the use of entrectinib in ROS1 TKI-naïve ROS1 fusion-positive NSCLC [155]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.